Coverage Policies

Important! Please note:

Current policies effective through April 30, 2024.

Use the index below to search for coverage information on specific medical conditions.

High-Tech Imaging: High-Tech Imaging services are administered by Evolent. For coverage information and authorizations, click here.

Medical Providers: Payment for care or services is based on eligibility, medical necessity and available benefits at time of service and is subject to all contractual exclusions and limitations, including pre-existing conditions if applicable.

Future eligibility cannot be guaranteed and should be rechecked at time of service. Verify benefits by signing into My Account or calling Customer Service at 800.235.7111 or 501.228.7111.

QualChoice follows care guidelines published by MCG Health.

Clinical Practice Guidelines for Providers (PDF)

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.

INDEX:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Effective Date: 07/01/2022 Title: Tezpire
Revision Date: Document: BI705:00
CPT Code(s): J2356
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Tezspire (Tezepelumab) requires prior authorization.

2)      Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.


Medical Statement

Initial Approval Criteria A. Severe Asthma (must meet all):

1. Diagnosis of asthma;

2. Prescribed by or in consultation with an allergist, immunologist, or pulmonologist;

3. Age ≥ 12 years;

4. Member has experienced ≥ 2 exacerbations with in the last 12 months, requiring any of the following despite adherent use of controller therapy (i.e., medium- to high-dose inhaled corticosteroid [ICS] plus either a long acting beta-2 agonist [LABA] or leukotriene modifier [LTRA] if LABA contraindication/intolerance):

a. Oral/systemic corticosteroid treatment (or increase in dose if already on oral corticosteroid);

b. Urgent care visit or hospital admission;

c. Intubation;

 

5. Tezspire is prescribed concurrently with an ICS plus either a LABA or LTRA;

6. Tezspire is not prescribed concurrently with Cinqair®, Dupixent®, Fasenra®, Nucala®, or Xolair®;

7. Dose does not exceed 210 mg every 4 weeks.

Approval duration: 6 months

 

 

Continued Therapy

A. Severe Asthma (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

2. Demonstrated adherence to asthma controller therapy (an ICS plus either a LABA or LTRA) as evidenced by proportion of days covered (PDC) of 0.8 in the last 6 months (i.e., member has received asthma controller therapy for at least 5 of the last 6 months);

3. Member is responding positively to therapy (examples may include but are not limited to: reduction in exacerbations or corticosteroid dose, improvement in forced expiratory volume over one second since baseline, reduction in the use of rescue therapy);

4. Tezspire is not prescribed concurrently with Cinqair, Dupixent, Fasenra, Nucala, or Xolair;

5. If request is for a dose increase, new dose does not exceed 210 mg every 4 weeks.

Approval duration: 6 months or member’s renewal period, whichever is longer

 

Codes Used In This BI:

 

1)    J2356 – Injection, Tezepelumab-ekko, 1mg


Reference

1. Tezspire Prescribing Information. Thousand Oaks, CA: Amgen; December 2021. Available at: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/tezspire/tezspire_pi_hcp_english.ashx. Accessed January 10, 2022.

2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med 2017;377:936-46.

3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med 2021;384:1800-9.

4. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Available at http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines. Accessed September 21, 2021.

5. Cloutler MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults 2020: asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020; 324: 2301-2317.

6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://www.clinicalpharmacology.com. Accessed September 24, 2021.

7. Global Initiative for Asthma. Global strategy for asthma management and prevention (2021 report). Available from: www.ginasthma.org. Accessed September 21, 2021.


Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
This policy has recently been updated. Please use the index above or enter policy title in search bar for the latest version.